Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ab&B Bio-Tech CO., LTD. JS Class H ( (HK:2627) ) has issued an announcement.
Ab&B Bio-Tech Co., Ltd. JS has moved to fill the vacancy created by the resignation of Deloitte Touche Tohmatsu by proposing the appointment of Prism Hong Kong Limited as its new auditor, subject to shareholder approval at a general meeting. The new auditor would serve until the next annual general meeting, a key step as the company works through delayed 2025 results and a trading suspension in its shares.
The audit committee and board selected Prism after a competitive process that assessed qualifications, independence, fees, resources and scope in line with Accounting and Financial Reporting Council guidelines. Prism, which audits more than 70 Hong Kong-listed companies including biotech and healthcare issuers, has proposed an enhanced, risk-based first-year audit focusing on areas such as revenue recognition, credit losses and asset impairments to address issues highlighted by earlier announcements.
More about Ab&B Bio-Tech CO., LTD. JS Class H
Ab&B Bio-Tech Co., Ltd. JS is a Chinese biotechnology company listed in Hong Kong, focusing on biotech-related products and operating through subsidiaries in the People’s Republic of China. The group is part of the broader biotech, pharmaceutical and healthcare ecosystem, and its shares trade on the Stock Exchange of Hong Kong under stock code 2627.
Average Trading Volume: 793,219
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$11.54B
For a thorough assessment of 2627 stock, go to TipRanks’ Stock Analysis page.